Loading…
Loading…
CNCR (Loncar Cancer Immunotherapy ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Is CNCR's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
SFYX, CNCR, FXN and DIV are included in this Analyst Blog.
Low-priced ETFs could be attractive for investors as these enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.
Wall Street roars back from its biggest weekly losses of the year, driven by bargain hunting and looming Fed rate cuts.
Wall Street was upbeat last week on Fed rate cut hopes.